| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | U22 |
| Uniprot No | Q69557 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-202aa |
| 氨基酸序列 | SLHIINNENSVFIATHSETELRHWLIFVKMAQRNGTAWWRMASVPINAYFERDIAFLFNPRCVIETAMGSKILCRYNKNIGVVFVDNDTKCNVSFPSGVQLQLLNQSVMESIRTKTYVVDYARKTTERGDCFISVAFCRKERRRFLSRCERFVYYCISVYLFAVVVLCSCWFALDPLFNMWA |
| 预测分子量 | 24.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于学术文献的模拟示例，供参考(注：U22相关研究较少，以下为假设性示例，建议核实具体研究方向)：
1. **文献名称**: "Expression and functional characterization of recombinant U22 glycoprotein in HSV-1 entry"
**作者**: Zhang L., et al.
**摘要**: 本研究在大肠杆菌系统中表达了HSV-1 UL22基因的重组蛋白，证实其通过与宿主细胞膜受体相互作用促进病毒入侵，并解析了其关键结构域的功能。
2. **文献名称**: "U22 recombinant protein as a novel immune modulator in murine models"
**作者**: Gupta R., et al.
**摘要**: 通过杆状病毒系统表达哺乳动物U22蛋白，发现其能增强Th1型免疫反应，在疫苗佐剂开发中具有潜在应用价值。
3. **文献名称**: "Structural analysis of U22 protein from Epstein-Barr virus using cryo-EM"
**作者**: Müller B., et al.
**摘要**: 利用冷冻电镜解析EB病毒U22蛋白的三维结构，揭示了其与病毒衣壳组装相关的关键氨基酸位点，为抗病毒药物设计提供依据。
4. **文献名称**: "High-yield purification of recombinant U22 protein and its antimicrobial activity screening"
**作者**: Chen X., et al.
**摘要**: 开发了基于亲和层析的U22重组蛋白纯化工艺，发现其对革兰氏阳性菌具有抑菌活性，机制可能与细胞壁合成干扰有关。
**注意**：以上文献为示例性质，实际研究中请通过PubMed/Google Scholar以“U22 protein”、“UL22 recombinant”等关键词检索真实文献，并依据具体研究领域(病毒学/免疫学等)筛选。若涉及罕见蛋白，建议结合UniProt数据库(ID: [检索U22])确认标准命名。
U22 recombinant protein, often associated with viral or cellular origin depending on context, is a engineered biomolecule generated through recombinant DNA technology. The term "U22" may refer to specific viral proteins, such as those encoded by Epstein-Barr virus (EBV) or other herpesviruses, where U22 denotes a unique open reading frame (ORF) involved in viral replication, immune evasion, or structural assembly. In cellular contexts, U22-like proteins may participate in intracellular signaling, membrane trafficking, or immune modulation, though nomenclature varies across studies. Recombinant U22 is typically produced by cloning the target gene into expression vectors (e.g., bacterial, yeast, or mammalian systems), followed by purification via chromatography. Its applications span biomedical research, including antigen production for antibody development, structural studies to elucidate viral mechanisms, and therapeutic exploration, such as vaccine candidates or immune-modulating agents. Recent studies focus on U22's role in pathogen-host interactions, particularly its potential as a diagnostic marker or drug target. Challenges include optimizing expression yields, maintaining protein stability, and ensuring functional fidelity. Research on U22 recombinant proteins contributes to virology, immunology, and targeted therapy development, though precise biological roles and clinical relevance require further validation. Current investigations also explore its utility in nanotechnology and targeted drug delivery systems due to potential binding specificity. Ethical and safety considerations in handling viral-derived proteins remain critical in translational applications.
×
